Juan Camilo Arjona Ferreira - May 26, 2021 Form 4 Insider Report for Myovant Sciences Ltd. (MYOV)

Role
Chief Medical Officer
Signature
/s/ Matthew Lang, Attorney-in-fact
Stock symbol
MYOV
Transactions as of
May 26, 2021
Transactions value $
-$208,915
Form type
4
Date filed
5/28/2021, 04:35 PM
Next filing
Jun 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYOV Common Shares Options Exercise $98.8K +12.7K +7.14% $7.78 191K May 26, 2021 Direct
transaction MYOV Common Shares Sale -$308K -12.7K -6.66% $24.23 178K May 26, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MYOV Stock Option (Right to Buy) Options Exercise $0 -9.83K -13.37% $0.00 63.7K May 26, 2021 Common Shares 9.83K $7.78 Direct F3
transaction MYOV Stock Option (Right to Buy) Options Exercise $0 -2.87K -1.5% $0.00 188K May 26, 2021 Common Shares 2.87K $7.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares sold pursuant to a 10b5-1 trading plan.
F2 The shares were sold at prices ranging from $24.00 to $24.87. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.
F4 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.